Uchida Naotaka, Ishiguro Kiyosuke, Suda Takako, Nishimura Motonobu
Division of Organ Regeneration Surgery, Dept. of Surgery, Tottori University Faculty of Medicine.
Gan To Kagaku Ryoho. 2009 Dec;36(13):2619-22.
A 42-year-old woman came to our hospital complaining of an enlarging tumor in her right breast. A core needle biopsy of the involved area demonstrated primary squamous cell carcinoma (SCC) of the breast. Preoperative neoadjuvant chemotherapies included 5-fluorouracil: 5-FU+epirubicin: EPI+cyclophosphamide: CPA (FEC), paclitaxel (PTX), vinorelbine (VNR) and 5-FU+nedaplatin (254-S) given in the order listed, but the mass continued to enlarge. Therefore, surgical resection was performed. Local recurrence and lung metastasis occurred after surgery. Although postoperative adjuvant chemotherapy consisting of carboplatin (CBDCA) +etoposide (VP-16) was administered, the patient died three months after surgery. SCC of the breast is generally treated according to clinical stage using protocol for common types of breast cancer. However, effective regimens have not been established for SCC, because it tends to be treatment-refractory. Therefore, in patients with SCC, it is important to consider surgery at an earlier stage than would be considered for a common breast cancer requiring preoperative neoadjuvant chemotherapy.
一名42岁女性因右侧乳房肿物增大前来我院就诊。对病变区域进行粗针穿刺活检，结果显示为原发性乳腺鳞状细胞癌（SCC）。术前新辅助化疗方案依次为5-氟尿嘧啶（5-FU）+表柔比星（EPI）+环磷酰胺（CPA）（FEC方案）、紫杉醇（PTX）、长春瑞滨（VNR）以及5-FU+奈达铂（254-S），但肿块仍持续增大。因此，进行了手术切除。术后出现局部复发和肺转移。尽管给予了由卡铂（CBDCA）+依托泊苷（VP-16）组成的术后辅助化疗，但患者术后三个月死亡。乳腺SCC通常根据临床分期采用常见类型乳腺癌的治疗方案进行治疗。然而，由于SCC往往对治疗耐药，尚未确立有效的治疗方案。因此，对于SCC患者，与需要术前新辅助化疗的常见乳腺癌相比，更早考虑手术治疗非常重要。
